SMMT

Summit Therapeutics is a development-stage biopharmaceutical company with no product revenue and a single lead asset: ivonescimab, a PD-1/VEGF bispecific antibody in-licensed from Akeso for the US, Europe, Canada, Japan and other territories. The financials are those of a clinical-stage bet: FY2025 net loss of -$1.08B, operating cash flow of -$323M, an accumulated deficit of -$2.29B, and a -163.9% ROE. There is no revenue line to value against, so the stock is priced entirely on the probability and size of future approval and commercialization.

There is a genuine catalyst, which is why this is not a zero-conviction avoid. In May 2025 the Phase III HARMONi study hit its primary PFS endpoint with a statistically significant hazard ratio of 0.52 (median PFS 6.8 vs 4.4 months), though overall survival showed only a positive trend without statistical significance. In January 2026 the FDA accepted the ivonescimab BLA with a PDUFA target action date of November 14, 2026. A favorable decision could transform the company; a delay, denial, or weak OS data could sharply impair it.